About Genprex, Inc.
https://www.genprex.comGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
CEO
Ryan M. Confer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-10-21 | Reverse | 1:50 |
| 2024-02-02 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:433.37K
Value:$1.24M
SUSQUEHANNA INTERNATIONAL GROUP, LLP
Shares:340.06K
Value:$975.96K
JANE STREET GROUP, LLC
Shares:205.18K
Value:$588.87K
Summary
Showing Top 3 of 25
About Genprex, Inc.
https://www.genprex.comGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.35M ▼ | $-3.8M ▲ | 0% | $-5 ▲ | $-3.8M ▲ |
| Q2-2025 | $0 | $4.68M ▲ | $-4.67M ▼ | 0% | $-8.5 ▲ | $-4.68M ▼ |
| Q1-2025 | $0 | $3.97M ▼ | $-3.96M ▲ | 0% | $-13 ▲ | $-3.97M ▲ |
| Q4-2024 | $0 | $4.34M ▲ | $-4.33M ▼ | 0% | $-21 ▲ | $-4.33M ▼ |
| Q3-2024 | $0 | $4.32M | $-4.32M | 0% | $-61.5 | $-4.31M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.1M ▼ | $3.56M ▼ | $2.79M ▲ | $767.81K ▼ |
| Q2-2025 | $1.35M ▼ | $3.83M ▼ | $2.44M ▲ | $1.39M ▼ |
| Q1-2025 | $3.47M ▲ | $6.01M ▲ | $2.14M ▼ | $3.87M ▲ |
| Q4-2024 | $1.6M ▲ | $4.12M ▲ | $2.5M ▲ | $1.62M ▼ |
| Q3-2024 | $1.49M | $3.91M | $2.24M | $1.66M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.8M ▲ | $-3.19M ▲ | $0 | $2.94M ▲ | $-243.53K ▲ | $-3.19M ▲ |
| Q2-2025 | $-4.67M ▼ | $-3.86M ▲ | $0 | $1.74M ▼ | $-2.12M ▼ | $-3.86M ▲ |
| Q1-2025 | $-3.96M ▲ | $-4.16M ▼ | $0 | $6.03M ▲ | $1.87M ▲ | $-4.16M ▼ |
| Q4-2024 | $-4.33M ▼ | $-3.87M ▼ | $0 ▲ | $3.98M ▲ | $113.38K ▲ | $-3.87M ▼ |
| Q3-2024 | $-4.32M | $-1.41M | $-773.48K | $1.22M | $-970.74K | $-1.41M |
CEO
Ryan M. Confer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-10-21 | Reverse | 1:50 |
| 2024-02-02 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:433.37K
Value:$1.24M
SUSQUEHANNA INTERNATIONAL GROUP, LLP
Shares:340.06K
Value:$975.96K
JANE STREET GROUP, LLC
Shares:205.18K
Value:$588.87K
Summary
Showing Top 3 of 25